Title:
ANTIPSYCHOTIC AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/079993
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a novel therapeutic drug for mental illness with abnormal neurodevelopment. Provided is an antipsychotic containing a Rho kinase inhibitor as an active ingredient. The antipsychotic can be utilized, for example, in the treatment of schizophrenia, autism spectrum disorders, bipolar disorder, or depression.
Inventors:
OZAKI NORIO (JP)
YAMADA KIYOFUMI (JP)
NAGAI TAKU (JP)
MORI DAISUKE (JP)
ARIOKA YUKO (JP)
KUSHIMA ITARU (JP)
YAMADA KIYOFUMI (JP)
NAGAI TAKU (JP)
MORI DAISUKE (JP)
ARIOKA YUKO (JP)
KUSHIMA ITARU (JP)
Application Number:
PCT/JP2019/035488
Publication Date:
April 23, 2020
Filing Date:
September 10, 2019
Export Citation:
Assignee:
UNIV NAGOYA NAT UNIV CORP (JP)
International Classes:
A61K45/00; A61K31/551; A61P25/00; A61P25/18; A61P25/24; A61P43/00
Foreign References:
| JP2011519972A | 2011-07-14 | |||
| JP2018194682A | 2018-12-06 | |||
| JP2018015304W | 2018-04-11 |
Other References:
GARCIA-ROJO, GONZALO ET AL.: "The ROCK Inhibitor Fasudil Prevents Chronic Restraint Stress-Induced Depressive-Like Behaviors and Dendritic Spine Loss in Rat Hippocampus", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, vol. 20, no. 4, 2017, pages 336 - 345, XP055702207
MEZIANE, HAMID ET AL.: "Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligophrenin-1 mouse model of intellectual disability", HUMAN MOLECULAR GENETICS, vol. 25, no. 11, 2016, pages 2314 - 2323, XP055702205
WROBEL, ANDRZEJ ET AL.: "Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 837, 30 August 2018 (2018-08-30), pages 127 - 136, XP085479383, DOI: 10.1016/j.ejphar.2018.08.027
INAN, SALIM YALCIN ET AL.: "Infralimbic cortex Rho-kinase inhibition causes antidepressant-like activity in rats", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 57, 3 March 2015 (2015-03-03), pages 36 - 43, XP055702199
LI, LI ET AL.: "Selective targeting of M-type potassium Kv7.4 channels demonstrates their key role in the regulation of dopaminergic neuronal excitability and depression-like behaviour", BRITISH JOURNAL OF PHARMACOLOGY, vol. 174, no. 23, December 2017 (2017-12-01), pages 4277 - 4294, XP055702195
SWANGER, SHARON A. ET AL.: "ROCK1 and ROCK2 inhibition alters dendritic spine morphology in hippocampal neurons", CELLULAR LOGISTICS, vol. 5, no. 4, 2015, XP055702191
KUSHIMA I. ET AL.: "High-resolution copy number variation analysis of schizophrenia in Japan", MOL PSYCHIATRY, vol. 22, 2017, pages 430 - 440
TRANSL PSYCHIATRY, vol. 8, no. 1, 19 July 2018 (2018-07-19), pages 129
CADINU D. ET AL.: "NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update", NEUROPHARMACOLOGY, vol. 17, no. 30584-1, 2017, pages S0028 - 3908
HOWES 0.MCCUTCHEON RSTONE J.: "Glutamate and dopamine in schizophrenia: an update for the 21st century", J PSYCHOPHARMACOL, vol. 29, 2015, pages 97 - 115
IBI D. ET AL.: "Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood", BEHAV BRAIN RES, vol. 206, 2010, pages 32 - 37, XP026709950, DOI: 10.1016/j.bbr.2009.08.027
JAVITT D. C. ET AL.: "Recent advances in the phencyclidine model of schizophrenia", AM J PSYCHIATRY, vol. 148, 1991, pages 1301 - 1308
KRYSTAL J.H. ET AL.: "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses", ARCH GEN PSYCHIATRY, vol. 51, 1994, pages 199 - 214
LIEBERMAN J.A.KANE J.M.ALVIR J.: "Provocative tests with psychostimulant drugs in schizophrenia", PSYCHOPHARMACOLOGY, vol. 91, 1987, pages 415 - 33
NEILL J.C. ET AL.: "Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism", PHARMACOL THER, vol. 128, 2010, pages 419 - 432, XP027445811, DOI: 10.1016/j.pharmthera.2010.07.004
TAMMINGA C.A. ET AL.: "Glutamate pharmacology and the treatment of schizophrenia: current status and future directions", INT CLIN PSYCHOPHARMACOL, vol. 10, 1995, pages 29 - 37, XP008084759, DOI: 10.1097/00004850-199509000-00005
VOLKOW N.D. ET AL.: "Neuropsychiatric disorders: investigation of schizophrenia and substance abuse", SEMIN NUCL MED, vol. 22, 1992, pages 254 - 267
WULAER B. ET AL.: "Repetitive and compulsive-like behaviors lead to cognitive dysfunction in Disc162-3/62-3 mice", GENES BRAIN BEHAV, 10 April 2018 (2018-04-10), pages e12478
MEZIANE, HAMID ET AL.: "Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligophrenin-1 mouse model of intellectual disability", HUMAN MOLECULAR GENETICS, vol. 25, no. 11, 2016, pages 2314 - 2323, XP055702205
WROBEL, ANDRZEJ ET AL.: "Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 837, 30 August 2018 (2018-08-30), pages 127 - 136, XP085479383, DOI: 10.1016/j.ejphar.2018.08.027
INAN, SALIM YALCIN ET AL.: "Infralimbic cortex Rho-kinase inhibition causes antidepressant-like activity in rats", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 57, 3 March 2015 (2015-03-03), pages 36 - 43, XP055702199
LI, LI ET AL.: "Selective targeting of M-type potassium Kv7.4 channels demonstrates their key role in the regulation of dopaminergic neuronal excitability and depression-like behaviour", BRITISH JOURNAL OF PHARMACOLOGY, vol. 174, no. 23, December 2017 (2017-12-01), pages 4277 - 4294, XP055702195
SWANGER, SHARON A. ET AL.: "ROCK1 and ROCK2 inhibition alters dendritic spine morphology in hippocampal neurons", CELLULAR LOGISTICS, vol. 5, no. 4, 2015, XP055702191
KUSHIMA I. ET AL.: "High-resolution copy number variation analysis of schizophrenia in Japan", MOL PSYCHIATRY, vol. 22, 2017, pages 430 - 440
TRANSL PSYCHIATRY, vol. 8, no. 1, 19 July 2018 (2018-07-19), pages 129
CADINU D. ET AL.: "NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update", NEUROPHARMACOLOGY, vol. 17, no. 30584-1, 2017, pages S0028 - 3908
HOWES 0.MCCUTCHEON RSTONE J.: "Glutamate and dopamine in schizophrenia: an update for the 21st century", J PSYCHOPHARMACOL, vol. 29, 2015, pages 97 - 115
IBI D. ET AL.: "Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood", BEHAV BRAIN RES, vol. 206, 2010, pages 32 - 37, XP026709950, DOI: 10.1016/j.bbr.2009.08.027
JAVITT D. C. ET AL.: "Recent advances in the phencyclidine model of schizophrenia", AM J PSYCHIATRY, vol. 148, 1991, pages 1301 - 1308
KRYSTAL J.H. ET AL.: "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses", ARCH GEN PSYCHIATRY, vol. 51, 1994, pages 199 - 214
LIEBERMAN J.A.KANE J.M.ALVIR J.: "Provocative tests with psychostimulant drugs in schizophrenia", PSYCHOPHARMACOLOGY, vol. 91, 1987, pages 415 - 33
NEILL J.C. ET AL.: "Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism", PHARMACOL THER, vol. 128, 2010, pages 419 - 432, XP027445811, DOI: 10.1016/j.pharmthera.2010.07.004
TAMMINGA C.A. ET AL.: "Glutamate pharmacology and the treatment of schizophrenia: current status and future directions", INT CLIN PSYCHOPHARMACOL, vol. 10, 1995, pages 29 - 37, XP008084759, DOI: 10.1097/00004850-199509000-00005
VOLKOW N.D. ET AL.: "Neuropsychiatric disorders: investigation of schizophrenia and substance abuse", SEMIN NUCL MED, vol. 22, 1992, pages 254 - 267
WULAER B. ET AL.: "Repetitive and compulsive-like behaviors lead to cognitive dysfunction in Disc162-3/62-3 mice", GENES BRAIN BEHAV, 10 April 2018 (2018-04-10), pages e12478
Attorney, Agent or Firm:
HAGINO Mikiharu (JP)
Download PDF: